Results 21 to 30 of about 4,122,734 (351)

Phenotype overlap in the natural history of asthma

European Respiratory Review, 2023
The heterogeneity of asthma makes it challenging to unravel the pathophysiologic mechanisms of the disease. Despite the wealth of research identifying diverse phenotypes, many gaps still remain in our knowledge of the disease's complexity.
Fabio L.M. Ricciardolo, Giuseppe Guida, Francesca Bertolini, Antonino Di Stefano, Vitina Carriero   +4 more
doaj   +1 more source

Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial.

Journal of Allergy and Clinical Immunology, 2021
BACKGROUND The interleukin (IL)-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens, pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-33, an epithelial-derived "alarmin." Astegolimab, a ...
S. Kelsen, I. Agache, W. Soong, E. Israel, G. Chupp, D. Cheung, Wiebke Theess, Xiaoying Yang, Tracy Staton, D. Choy, Alice Fong, A. Dash, Michael Dolton, R. Pappu, C. Brightling   +14 more
semanticscholar   +1 more source

What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance

ERJ Open Research, 2021
There is an increasing number of new therapies for severe asthma; however, what outcomes people with severe asthma would like improved and what aspects they prioritise in new medications remain unknown.
Vanessa L. Clark, Peter G. Gibson, Vanessa M. McDonald   +2 more
doaj   +1 more source

“It's like being on a roller coaster”: the burden of caring for people with severe asthma

ERJ Open Research, 2021
Introduction Family carers and significant others play a fundamental role in the well-being of people with severe asthma. This study aimed to investigate the challenges faced by family carers/significant others of people with severe asthma, to understand
Eleanor C. Majellano, Vanessa L. Clark, Juliet M. Foster, Peter G. Gibson, Vanessa M. McDonald   +4 more
doaj   +1 more source

Defining a severe asthma super-responder: findings from a Delphi process.

Journal of Allergy and Clinical Immunology: In Practice, 2021
BACKGROUND Clinicians are increasingly recognising severe asthma patients in whom biologicals and other add-on therapies lead to dramatic improvement. Currently, there is no agreed upon super-responder (SR) definition. OBJECTIVE To survey severe asthma
J. Upham, C. L. Le Lievre, D. Jackson, M. Masoli, M. Wechsler, D. Price   +5 more
semanticscholar   +1 more source

Difficult‐to‐treat asthma patients from ethnic minority groups in central England are at an enhanced risk of house dust mite sensitisation

Clinical and Translational Allergy, 2023
Background House dust mite (HDM) is the most common sensitising allergen in asthma. Ethnic minority groups (EMGs) in the UK are more likely to live in deprived conditionings with a greater exposure to HDM and other aero‐allergens.
Adel H. Mansur, Julie Marsh, Ali Bahron, Maximillian Thomas, Gareth Walters, John Busby, Liam G. Heaney, Mamidipudi Thirumala Krishna   +7 more
doaj   +1 more source

T helper 17 cells and corticosteroid insensitivity in severe asthma.

Journal of Allergy and Clinical Immunology, 2021
Asthma is classically described as either a T2 eosinophilic phenotype or a non-T2 neutrophilic phenotype. T2 asthma usually responds to classical bronchodilation therapy and corticosteroid treatment.
Yan Xie, P. Abel, T. Casale, Y. Tu
semanticscholar   +1 more source

Severe Asthma in a General Population Study: Prevalence and Clinical Characteristics

Journal of Asthma and Allergy, 2021
Purpose Current guidelines primarily use medication levels to distinguish severe asthma from other types of asthma. In addition, severe asthma must also be uncontrolled at high-intensity treatment or become uncontrolled if treatment level is decreased ...
Lina Rönnebjerg, Malin Axelsson, Hannu Kankaanranta, H. Backman, M. Rådinger, B. Lundbäck, L. Ekerljung   +6 more
semanticscholar   +1 more source

Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial.

New England Journal of Medicine, 2021
BACKGROUND Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear ...
C. Brightling, Parameswaran Nair, David J. Cousins, R. Louis, Dave Singh   +4 more
semanticscholar   +1 more source

Dupilumab modulates specific IgE mite responses at the molecular level in severe T2-high atopic dermatitis: A real-world experience

Frontiers in Medicine, 2022
BackgroundAtopic dermatitis (AD) is regarded as a chronic systemic disease which is characterized by a robust overexpression of type 2 related cytokines, with increased total IgE levels and a concomitant sensitization to common allergens.
Ruperto González-Pérez, Ruperto González-Pérez, Paloma Poza-Guedes, Paloma Poza-Guedes, Elena Mederos-Luis, Inmaculada Sánchez-Machín   +5 more
doaj   +1 more source